$40.78
0.44% today
Nasdaq, Nov 12, 10:13 pm CET
ISIN
US92686J1060
Symbol
VKTX

Viking Therapeutics, Inc. Stock price

$40.78
+6.87 20.26% 1M
+12.48 44.10% 6M
+0.54 1.34% YTD
-19.82 32.71% 1Y
+36.45 841.80% 3Y
+34.69 569.62% 5Y
+36.07 765.82% 10Y
+31.82 355.13% 20Y
Nasdaq, Closing price Wed, Nov 12 2025
+0.18 0.44%
ISIN
US92686J1060
Symbol
VKTX
Industry

New AI Insights on Viking Therapeutics, Inc. Insights AI Insights on Viking Therapeutics, Inc.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$4.2b
Enterprise Value
$3.5b
Net debt
positive
Cash
$714.6m
Shares outstanding
112.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.9
Financial Health
Equity Ratio
96.9%
Return on Equity
-12.5%
ROCE
-38.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-301.5m
EBIT
$-274.8m | $-313.2m
Net Income
$-237.4m | $-302.2m
Free Cash Flow
$-224.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -100.2%
EBIT
-105.2% | -107.5%
Net Income
-139.4% | -174.8%
Free Cash Flow
-202.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.1
FCF per Share
$-2.0
Short interest
27.0%
Employees
46
Rev per Employee
$0.0
Show more

Is Viking Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,033 stocks worldwide.

Viking Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Viking Therapeutics, Inc. forecast:

21x Buy
91%
2x Hold
9%

Analyst Opinions

23 Analysts have issued a Viking Therapeutics, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Viking Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 52 52
22% 22%
-
- Research and Development Expense 222 222
144% 144%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -275 -275
105% 105%
-
Net Profit -237 -237
139% 139%
-

In millions USD.

Don't miss a Thing! We will send you all news about Viking Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viking Therapeutics, Inc. Stock News

Positive
The Motley Fool
3 days ago
Viking Therapeutics is developing innovative medicines in a fast-growing area. Axsome Therapeutics is generating strong sales, and solid regulatory progress could improve things.
Positive
The Motley Fool
3 days ago
Viking has initiated an exciting new phase 1 study combining an oral and subcutaneous formulation of a weight loss drug. The phase 1 trial results are expected next year, with the Phase 3 (subcutaneous) trial results scheduled for 2027.
Neutral
PRNewsWire
6 days ago
VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO , Nov. 6, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinic...
More Viking Therapeutics, Inc. News

Company Profile

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Brian Lian
Employees 46
Founded 2012
Website vikingtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today